NEW YORK (TheStreet) -- Achillion Pharmaceuticals
(ACHN) shares are rising, up 14.4% to $7.39 on Monday, after having its price target raised to $22 from $6 dollars by analysts at Maxim who also reiterated their "buy" rating.
The increased price target stems from the firm's faith in the intellectual property of the biopharmaceutical company's Hepatitis C nucleotide.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts